Shukui Qin Selected Research

Fatigue

1/2021	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
1/2021	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
1/2017	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
10/2013	Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
1/2009	Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shukui Qin Research Topics

Disease

76	Hepatocellular Carcinoma (Hepatoma) 06/2024 - 01/2009
54	Neoplasms (Cancer) 04/2024 - 05/2009
23	Hypertension (High Blood Pressure) 02/2024 - 04/2012
20	Disease Progression 11/2023 - 07/2011
18	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 05/2009
17	Stomach Neoplasms (Stomach Cancer) 11/2023 - 12/2011
15	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 06/2015
10	Adenocarcinoma 02/2024 - 12/2011
10	Neoplasm Metastasis (Metastasis) 10/2023 - 07/2014
8	Renal Cell Carcinoma (Grawitz Tumor) 01/2023 - 09/2012
8	Exanthema (Rash) 01/2019 - 07/2010
7	Liver Neoplasms (Liver Cancer) 12/2023 - 02/2002
7	Carcinoma (Carcinomatosis) 01/2023 - 01/2012
7	Diarrhea 02/2022 - 04/2012
6	Hand-Foot Syndrome 01/2023 - 11/2013
6	Neutropenia 11/2022 - 07/2010
6	Proteinuria 02/2022 - 01/2015
5	Fatigue 01/2021 - 01/2009
4	Hepatic Encephalopathy 02/2024 - 11/2020
4	Thrombocytopenia (Thrombopenia) 03/2020 - 11/2013
3	Multiple Organ Failure (MODS) 02/2024 - 01/2022
3	Biliary Tract Neoplasms (Biliary Tract Cancer) 11/2023 - 12/2021
3	Infections 02/2023 - 01/2016
3	Thyroid Neoplasms (Thyroid Cancer) 01/2023 - 01/2014
3	Hepatitis B 12/2021 - 11/2013
3	Fibrosis (Cirrhosis) 12/2021 - 02/2015
3	Breast Neoplasms (Breast Cancer) 01/2021 - 06/2017
3	Lung Neoplasms (Lung Cancer) 06/2018 - 08/2012
2	Sepsis (Septicemia) 02/2024 - 11/2022
2	Varicose Veins (Varicose Vein) 02/2024 - 01/2022
2	Tumor Lysis Syndrome 02/2024 - 01/2022
2	Chemical and Drug Induced Liver Injury 02/2024 - 01/2022
2	Hepatitis 02/2023 - 01/2019
2	Respiratory Insufficiency (Respiratory Failure) 01/2023 - 11/2020
2	Stomatitis 01/2023 - 11/2022
2	Pneumonia (Pneumonitis) 12/2022 - 11/2022
2	Microsatellite Instability 12/2022 - 01/2021
2	Hepatitis C 12/2021 - 11/2013
2	Starvation 12/2021 - 01/2014

Drug/Important Bio-Agent (IBA)

37	Sorafenib (BAY 43-9006)FDA Link 06/2024 - 01/2009
17	apatinibIBA 01/2024 - 09/2013
17	Oxaliplatin (Eloxatin)FDA LinkGeneric 05/2023 - 10/2013
13	Tyrosine Kinase InhibitorsIBA 01/2023 - 07/2011
12	Fluorouracil (Carac)FDA LinkGeneric 05/2023 - 10/2013
10	atezolizumabIBA 02/2024 - 01/2020
10	Bevacizumab (Avastin)FDA Link 11/2023 - 01/2015
9	camrelizumabIBA 01/2024 - 01/2020
9	Immune Checkpoint InhibitorsIBA 11/2023 - 01/2019
9	Leucovorin (Folinic Acid)FDA Link 05/2023 - 10/2013
8	HMPL-013IBA 04/2024 - 01/2018
8	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2024 - 07/2012
8	Gemcitabine FDA Link 11/2023 - 01/2011
8	Biomarkers (Surrogate Marker)IBA 06/2022 - 01/2017
7	Alanine Transaminase (SGPT)IBA 02/2024 - 07/2012
7	Cisplatin (Platino)FDA LinkGeneric 08/2022 - 09/2014
7	PlatinumIBA 12/2021 - 05/2009
6	Monoclonal AntibodiesIBA 02/2024 - 01/2017
6	lenvatinibIBA 12/2023 - 01/2018
6	Proteins (Proteins, Gene)FDA Link 03/2019 - 01/2014
5	pembrolizumabIBA 12/2023 - 01/2021
5	durvalumabIBA 12/2023 - 01/2021
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021 - 03/2013
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 03/2013
5	Trastuzumab (Herceptin)FDA Link 01/2021 - 02/2016
4	human ERBB2 proteinIBA 01/2023 - 02/2016
4	alpha-Fetoproteins (alpha-Fetoprotein)IBA 12/2022 - 07/2012
4	Phosphotransferases (Kinase)IBA 01/2022 - 01/2012
4	Capecitabine (Xeloda)FDA Link 01/2021 - 01/2015
4	Sunitinib (Sutent)FDA Link 03/2020 - 12/2011
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 02/2015
4	EndostatinsIBA 06/2018 - 08/2012
4	Axitinib (AG 013736)IBA 05/2018 - 01/2014
4	endostar proteinIBA 06/2015 - 08/2012
3	tislelizumabIBA 03/2024 - 06/2019
3	tepotinibIBA 02/2024 - 01/2018
3	tremelimumabIBA 12/2023 - 01/2021
3	surufatinibIBA 10/2023 - 11/2020
3	LigandsIBA 01/2023 - 01/2020
3	Angiogenesis InhibitorsIBA 01/2021 - 08/2012
3	regorafenibIBA 08/2020 - 06/2015
3	ErbB Receptors (EGF Receptor)IBA 01/2019 - 04/2012
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2019 - 05/2016
2	cabozantinibIBA 02/2024 - 01/2022
2	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 02/2024 - 11/2022
2	bemarituzumabIBA 02/2024 - 11/2022
2	ProdrugsIBA 06/2023 - 01/2022
2	Cetuximab (Erbitux)FDA Link 05/2023 - 10/2018
2	Everolimus FDA Link 01/2023 - 03/2013
2	IodineIBA 01/2023 - 02/2022
2	NivolumabIBA 01/2023 - 04/2020
2	donafenibIBA 01/2023 - 01/2021
2	RamucirumabIBA 12/2022 - 12/2021
2	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 01/2018
2	ginsenoside Rg3IBA 12/2021 - 06/2019
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2021 - 12/2017
2	Long Noncoding RNAIBA 12/2021 - 01/2021
2	Antineoplastic Agents (Antineoplastics)IBA 12/2021 - 02/2010

Therapy/Procedure

50	Therapeutics 01/2024 - 01/2009
45	Drug Therapy (Chemotherapy) 04/2024 - 05/2009
7	Immunotherapy 12/2023 - 12/2011